Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 7 of 7 publications.

Aiyegbusi OL, Cruz Rivera S, Roydhouse J, Kamudoni P, Alder Y, Anderson N, Baldwin RM, Bhatnagar V, Black J, Bottomley A, Brundage M, Cella D, Collis P, Davies EH, Denniston AK, Efficace F, Gardner A, Gnanasakthy A, Golub RM, Hughes SE, Jeyes F, Kern S, King-Kallimanis BL, Martin A, McMullan C, Mercieca-Bebber R, Monteiro J, Peipert JD, Quijano-Campos JC, Quinten C, Rantell KR, Regnault A, Sasseville M, Schougaard LMV, Sherafat-Kazemzadeh R, Snyder C, Stover AM, Verdi R, Wilson R, Calvert MJ. Recommendations to address respondent burden associated with patient-reported outcome assessment. Nat Med. 2024 Mar;30(3):650-9. doi: 10.1038/s41591-024-02827-9

Dickerman BA, Garcia-Albeniz X, Logan RW, Denaxas S, Hernan MA. Avoidable flaws in observational analyses: an application to statins and cancer. Nat Med. 2019 Oct;25(10):1601-6. doi: 10.1038/s41591-019-0597-x

Yosipovitch G, Reaney M, Eckert L, Nelson L, Clark M, Abbe A, Ardeleanu M, Radin A, Gadkari A. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adults with moderate-to-severe atopic dermatitis. Poster presented at the Australasian College of Dermatologists 50th Annual Scientific Meeting; May 2017. Sydney, Australia. [abstract] Australas J Dermatol. 2017 May; 58(S1):106-7. Previously presented at the 2017 American Academy of Dermatology Annual Meeting. doi: 10.1111/ajd.21_12652

Spelman LJ, Lebwohl M, Mordin M, Mallya UG, Gnanasakthy A, Fox T. Secukinumab treatment provides fast relief from patient-reported psoriasis burden. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):73.

Foley P, Sherif B, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):56.

Sinclair R, McLeod L, Mallya UG, Fox T, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(S2):68.

Ribeiro-Oliveira Jr A, Mol SS, Twiss J, Alencar GA, Miranda PA, Naves LA, Azevedo MF, Basilio FM, Boguszewski CL, Nogueira KC, Vilar L, Koltowska-Haggstrom M, McKenna SP. The brazilian version of the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA): four-stage translation and validation. Arq Bras Endocrinol Metabol. 2010 Dec;54(9):833-41.